XR9576: Phase I data; Phase II

XR9576 was well tolerated when given either intravenously to 30 or orally to 30 healthy volunteers in a Phase I placebo-controlled dose escalation study. Doses of 2 mg/kg iv or 750 mg orally gave comp...